ZLABZai Lab Ltd

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Companys potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that Chinas National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the...

Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corporate updates. We continue to accelerate the...

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight brokerages that are presently covering the firm...

Zai Lab (NASDAQ:ZLAB) hosted an investor call tied to the 2026 American Association for Cancer Research (AACR) meeting to highlight new data for its DLL3-targeted antibody-drug conjugate (ADC...

Zai Lab (NASDAQ:ZLAB) Shares Down 5.2% - What's Next...